Youngseo Na

Youngseo Na

Auto-generated profile, based on publicly available information

Youngseo Na

Department of Medicinal Chemistry, University of Michigan, Ann Arbor, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YCYoung Seok Cho
Young Seok Cho
XZXingwu Zhou
Xingwu Zhou
XSXiaoqi Sun
Xiaoqi Sun
ZWZiye Wan
Ziye Wan
JCJulia Crowther
Julia Crowther
JMJames Moon
James Moon
Toll-like receptor (TLR) agonists, as potent immunostimulatory adjuvants, play a critical role in linking the innate and adaptive immune responses. However, their antitumor effects as cancer immunotherapeutic agents have been limited. Here, we report our finding that manganese ion (Mn 2+ ) potentiates various TLR agonists, leading to robust activation of the TLR pathway and the stimulator of interferon genes (STING) pathway among innate immune cells. In particular, we have observed robust antitumor efficacy after intratumoral administration of a TLR3 agonist and Mn 2+ . To achieve systemic codelivery of TLR3 agonist and Mn 2+ , we have developed a low-molecular-weight poly(inosinic:cytidylic acid)-Mn 2+ coordination lipid nanoparticle (PLCMP). When administered intravenously in tumor-bearing mice, PLCMP successfully accumulated in tumor, induced innate immune activation, generated tumor-specific T cells, and exerted antitumor efficacy in TLR3- and STING-dependent manner without triggering overt toxicity. Moreover, PLCMP in combination with α-PD-1 therapy achieved long-lasting antitumor efficacy in multiple murine tumor models. Furthermore, vaccination with PLCMP carrying TC-1 tumor antigen peptide elicited strong antigen-specific CD8 + T cell responses and remodeled the tumor microenvironment, resulting in robust therapeutic efficacy. Overall, these results show that simultaneous activation of the TLR3 and STING pathways via PLCMP provides a promising strategy for immunotherapy and vaccination against cancer.

10 August 2026 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
KHKai Han
Kai Han
YCYoung Seok Cho
Young Seok Cho
MTMariko Takahashi
Mariko Takahashi
XZXingwu Zhou
Xingwu Zhou
HDHannah E. Dobson
Hannah E. Dobson
JMJames Moon
James Moon
Gut microbial metabolites play crucial roles in regulating systemic immunity, but their mechanisms and limited drug-like properties remain unresolved. Here we report an oral nano-formulation that leverages gut microbial metabolites to modulate T cell metabolism and amplify antitumour immunity. Through an in vitro screening of gut microbial metabolites, we identified 3,4-dihydroxybenzoic acid that improved adoptive T cell therapy and enhanced CD8+ T cell stemness by suppressing glycolysis and regulating the Akt-mTORC1-Myc pathway. To harness the potency of 3,4-dihydroxybenzoic acid for systemic cancer immunotherapy, we engineered a 3,4-dihydroxybenzoic acid prodrug nano-emulsion, significantly increasing its oral absorption and half-life. In multiple murine tumour models, the oral nano-emulsion enhanced the expansion of antigen-specific, stem-like CD8+ T cells, sensitizing tumours to anti-PD-1 blockade and exerting robust antitumour efficacy. By integrating nanotechnology with microbial-metabolite-based immunotherapy, this study establishes a mechanistic link between the gut microbiota and T cell immunity, offering a promising approach for cancer immunotherapy.

13 May 2023 in Protein Science
Verified
Journal Article
Closed access
Do-Hee KimDo-Hee Kim
Do-Hee Kim
YNYoungseo Na
Youngseo Na
HCHeesun Chang
Heesun Chang
JBJun‐Hyuk Boo
Jun‐Hyuk Boo
SKSung-Min Kang
Sung-Min Kang
BLBongjin Lee
Bongjin Lee